GT Biopharma, Inc. (GTBP)
Automate Your Wheel Strategy on GTBP
With Tiblio's Option Bot, you can configure your own wheel strategy including GTBP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GTBP
- Rev/Share 0.0
- Book/Share 1.7379
- PB 0.3897
- Debt/Equity 0.0
- CurrentRatio 3.088
- ROIC -2.2446
- MktCap 2408792.0
- FreeCF/Share -3.7597
- PFCF -0.2311
- PE -0.1998
- Debt/Assets 0.0
- DivYield 0
- ROE -8.8133
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts
Read More
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2.
Read More
GT Biopharma Announces Exercise of Warrants
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK”) cell engager platform, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 302,069 shares of its common stock having an exercise price of $4.35 per share, originally issued in May 2024. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration …
Read More
About GT Biopharma, Inc. (GTBP)
- IPO Date 2018-03-27
- Website https://www.gtbiopharma.com
- Industry Biotechnology
- CEO Alan Louis Urban CPA
- Employees 1